Johannes Wesling Klinikum Minden

At Johannes Wesling Klinikum Minden, the Zentrum für Innere Medizin Klinik für Haematologie und Onkologie is running a broad portfolio of studies in hemic and lymphatic diseases and neoplasms, focused on improving treatment outcomes for blood cancers and solid tumors.

• Studies in acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis are assessing new treatment strategies and better disease control.
• Research in lymphoma, melanoma, and gastroesophageal and colorectal cancer is evaluating more effective cancer therapies.
• Several trials aim to improve survival, reduce relapse risk, and support patients with advanced or hard-to-treat malignancies.

Overall, this site contributes to clinical research that seeks more precise and effective cancer care for patients with complex hematologic and solid tumor diseases.

The site has active research in immune system diseases and immune system processes, with a strong emphasis on autoimmune conditions such as systemic lupus erythematosus, systemic sclerosis, psoriatic arthritis, and giant cell arteritis.

• Trials are testing new therapies to reduce inflammation and improve symptom control in chronic autoimmune disease.
• Research also includes eosinophilic granulomatosis with polyangiitis, IgG4-related disease, and other immune-mediated disorders.
• Some studies focus on long-term safety, tolerability, and sustained disease control for people living with these conditions.

This research area reflects a clear effort to expand treatment options for patients with persistent immune-driven illness.

Clinical trials at the site also cover nervous system diseases and related pathological conditions, including acute ischemic stroke, sudden hearing loss, and selected brain tumors such as glioma, ependymoma, and medulloblastoma.

• Stroke studies are examining ways to improve recovery after vessel reopening and to reduce disability after an acute event.
• Neuro-oncology research is aimed at improving survival and functional outcomes in children, adolescents, and adults with brain tumors.
• Other studies are exploring whether new treatments can preserve or restore hearing in sudden sensorineural hearing loss.

These projects show a strong interest in both emergency neurological care and longer-term treatment improvement in brain-related disease.

Research in respiratory tract diseases includes studies in non-small cell lung cancer, small-cell lung cancer, and interstitial lung disease, as well as lung involvement linked to rheumatic disease.

• Several trials are evaluating new cancer treatments for advanced lung and esophageal tumors.
• Other studies focus on improving outcomes for patients with lung fibrosis and autoimmune-related lung disease.
• The overall goal is to refine treatment effectiveness while addressing serious respiratory complications.

At this hospital, respiratory research spans both oncology and chronic inflammatory lung conditions.

The site is also involved in cardiovascular diseases, including heart failure with preserved or mildly reduced ejection fraction and acute ischemic stroke, with additional attention to obesity-related cardiovascular risk.

• Studies are testing new approaches to reduce heart failure events and improve patient outcomes.
• Stroke-related work aims to improve recovery and functional status after emergency treatment.
• These trials are designed to strengthen both prevention and treatment in high-risk cardiovascular disease.

This area highlights the site’s role in research that addresses major causes of disability and hospitalization.

The research portfolio includes important studies in childhood and adolescent cancers, especially acute myeloid leukemia, Ewing sarcoma, medulloblastoma, and ependymoma.

• Trials are aimed at improving survival, lowering treatment-related harm, and refining care for younger patients.
• Some studies focus on better control of high-risk disease and reducing the chance of recurrence.
• Others examine how treatment can be adapted to support both effectiveness and quality of life.

These pediatric and adolescent studies demonstrate a commitment to advancing care in rare and serious cancers.

Additional work at the site extends to skin and connective tissue diseases and broader immune-mediated conditions, including psoriatic arthritis, systemic sclerosis, and cutaneous T-cell lymphoma.

• Research is evaluating therapies that may improve skin, joint, and systemic symptoms.
• Some trials are focused on reducing disease activity and slowing progression in chronic inflammatory disorders.
• There is also interest in treatments that may improve patient comfort and daily functioning.

These studies broaden the site’s clinical research profile beyond cancer into complex inflammatory and skin-related disease.